| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JAAD.2006.07.017 |
| P698 | PubMed publication ID | 17097378 |
| P50 | author | Steven R. Feldman | Q42775161 |
| Kim A. Papp | Q54269356 | ||
| P2093 | author name string | Shu Li | |
| Alan Menter | |||
| Alice B Gottlieb | |||
| Robert Evans | |||
| Cynthia Guzzo | |||
| Lisa T Dooley | |||
| Gerald D Weinstein | |||
| Cynthia Arnold | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 31.e1-15 | |
| P577 | publication date | 2006-09-06 | |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis | |
| P478 | volume | 56 |
| Q38840271 | A Review of Psoriasis, Therapies, and Suicide. |
| Q38084325 | A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. |
| Q39297511 | A dermatologist guide to immunogenicity |
| Q39601823 | A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study |
| Q37903995 | A refresher on herpes zoster, current status on vaccination, and the role of the dermatologist |
| Q36600085 | A subset of methylated CpG sites differentiate psoriatic from normal skin. |
| Q38858335 | A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis |
| Q38623340 | A systematic review on the efficacy and safety of Infliximab in patients with psoriasis |
| Q58434950 | Adalimumab for the treatment of severe psoriasis and psoriatic arthritis |
| Q37868389 | Advances in the treatment of moderate-to-severe plaque psoriasis |
| Q24234197 | Adverse effects of biologics: a network meta-analysis and Cochrane overview |
| Q38569794 | An overview of developing TNF-α targeted therapy for the treatment of psoriasis |
| Q33752359 | Anti-TNFα therapy in the management of psoriasis: experience of a state referral center |
| Q38152820 | Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response |
| Q38151757 | Antidrug antibodies in psoriasis: a systematic review |
| Q37998917 | Application of the dermatology life quality index in clinical trials of biologics for psoriasis |
| Q92616693 | Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response |
| Q44771208 | Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. |
| Q38123192 | Biologic fatigue in psoriasis. |
| Q38366432 | Biologic response modifiers and pediatric psoriasis |
| Q30904076 | Biologic safety in psoriasis: review of long-term safety data |
| Q30412650 | Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring |
| Q38020037 | Biologic therapy in psoriasis: perspectives on associated risks and patient management |
| Q48236525 | Biologic treatments for elderly patients with psoriasis. |
| Q37307801 | Biological drugs targeting the immune response in the therapy of psoriasis |
| Q43078162 | Biological markers in the etiology of psoriasis: Targeted treatment options |
| Q38155648 | Biological therapies for psoriasis |
| Q39070719 | Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis. |
| Q41145989 | Biological therapy of psoriasis |
| Q38084746 | Biological treatments for moderate-to-severe psoriasis: indirect comparison. |
| Q41120913 | Biologics in dermatology: adverse effects |
| Q34620257 | Biologics in the management of psoriasis. |
| Q37607414 | Biologics in the treatment of psoriasis: clinical and economic overview |
| Q38586044 | Biosimilar monoclonal antibodies: the scientific basis for extrapolation |
| Q43720865 | Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study |
| Q38212907 | Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies |
| Q34502118 | Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab |
| Q38257403 | Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response |
| Q38042475 | Comparative efficacy of biologics in psoriasis: a review. |
| Q89545337 | Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis |
| Q33735385 | Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients |
| Q38108567 | Cost effectiveness of biologic therapies for plaque psoriasis. |
| Q46210972 | Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis |
| Q38039491 | Current and emerging systemic treatment strategies for psoriasis |
| Q28238060 | Current and future management of psoriasis |
| Q38831055 | Current challenges and emerging drug delivery strategies for the treatment of psoriasis |
| Q36057909 | Current status and future prospects for biologic treatments of psoriasis |
| Q34112840 | Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents |
| Q90742565 | Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis |
| Q34516612 | Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR) |
| Q37566094 | Depression and quality of life in psoriasis |
| Q39453926 | Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases |
| Q44477550 | Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel. |
| Q58764407 | Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos |
| Q37718987 | Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review |
| Q38104769 | Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. |
| Q57995214 | Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States |
| Q38064467 | Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses |
| Q34166896 | Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data? |
| Q38517070 | Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis |
| Q41957838 | Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle |
| Q38268725 | Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials. |
| Q51037967 | Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). |
| Q48593444 | Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). |
| Q38153077 | Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials |
| Q36190962 | Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| Q38137277 | Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points |
| Q33896449 | Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry |
| Q90465560 | Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis |
| Q34190076 | Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment |
| Q57244448 | Emerging drugs for psoriasis |
| Q37857668 | Emerging treatments in the management of psoriasis: biological targeting with ustekinumab |
| Q41561618 | Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. |
| Q37131025 | From conventional to cutting edge: the new era of biologics in treatment of psoriasis |
| Q58921879 | Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice |
| Q37151335 | Hepatitis and Lupus-Like Syndrome during Infliximab Therapy for Psoriasis |
| Q38238100 | Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials |
| Q34385556 | How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis |
| Q38150903 | Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? |
| Q38473460 | Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate |
| Q26827399 | Immunogenicity of biotherapy used in psoriasis: the science behind the scenes |
| Q33625546 | Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials |
| Q38920322 | Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study |
| Q37987269 | Implementing treatment goals for successful long-term management of psoriasis |
| Q43628810 | Incidence and risk factors for treatment failure with infliximab in psoriasis. |
| Q92626116 | Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events |
| Q37307554 | Infliximab for the treatment of plaque psoriasis. |
| Q37992139 | Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre. |
| Q38132707 | Infliximab in psoriasis and psoriatic arthritis. |
| Q38379864 | Interleukin-17 antagonists in the treatment of psoriasis |
| Q35407596 | Involvement of TNF-α converting enzyme in the development of psoriasis-like lesions in a mouse model |
| Q30675199 | Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? |
| Q38461733 | Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis |
| Q58921893 | Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice |
| Q37394846 | Long-term efficacy of biologics in dermatology |
| Q56982386 | Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response |
| Q48478885 | Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years |
| Q42640551 | Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. |
| Q30574065 | Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data |
| Q38286010 | Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions |
| Q53828883 | Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. |
| Q37930978 | Management of psoriatic arthritis from the view of the dermatologist |
| Q38960080 | Managing Scalp Psoriasis: An Evidence-Based Review. |
| Q26753038 | Nail Psoriasis: A Review of Treatment Options |
| Q38263098 | Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada |
| Q26827714 | Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy |
| Q47859049 | Old and New Biological Therapies for Psoriasis. |
| Q34107573 | Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease |
| Q90567424 | Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children |
| Q36368478 | Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. |
| Q37776736 | Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders |
| Q39144447 | Ponesimod--a future oral therapy for psoriasis? |
| Q38095548 | Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. |
| Q39668241 | Predictors of long-term drug survival for infliximab in psoriasis. |
| Q48234568 | Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis |
| Q58235909 | Psoriasis |
| Q34010557 | Psoriasis (chronic plaque) |
| Q33939033 | Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review |
| Q41812615 | Pustules and dystrophy of the nails. |
| Q27026785 | Putting together the psoriasis puzzle: an update on developing targeted therapies |
| Q49963125 | Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis |
| Q55687055 | Quo vadis, biological treatment for psoriasis and psoriatic arthritis? |
| Q38895147 | Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis |
| Q92798584 | Remicade® (infliximab): 20 years of contributions to science and medicine |
| Q37114650 | Review and clinical perspectives for the use of infliximab in ulcerative colitis |
| Q38836347 | Review of maintenance of response to psoriasis treatments |
| Q52888818 | S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. |
| Q48144965 | Safety of biologics in psoriasis. |
| Q38662868 | Secukinumab (AIN-457) for the treatment of Psoriasis |
| Q52922335 | Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. |
| Q38636359 | Secukinumab for treating plaque psoriasis |
| Q46453213 | Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis |
| Q46731189 | Serious infections among a large cohort of subjects with systemically treated psoriasis |
| Q35155926 | Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity |
| Q64229191 | Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials |
| Q38568183 | Systematic review on the maintenance of response during systemic antipsoriatic therapy |
| Q58573731 | Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab |
| Q47260366 | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. |
| Q36536861 | TNFalpha blockade in human diseases: an overview of efficacy and safety |
| Q26764867 | Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies |
| Q34393068 | The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. |
| Q37040371 | The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses |
| Q64901938 | The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature. |
| Q47644680 | The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis |
| Q38128354 | The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials |
| Q37722744 | The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. |
| Q42635096 | The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis |
| Q34984568 | The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials |
| Q91905537 | Therapeutic drug monitoring of biologics in psoriasis |
| Q48770670 | Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. |
| Q33412410 | Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials |
| Q38132706 | Treatment of psoriasis and psoriatic arthritis |
| Q37098135 | Treatment of severe psoriasis with infliximab |
| Q38937859 | Tumour necrosis factor-α plays a significant role in the Aldara-induced skin inflammation in mice. |
| Q34620375 | Update of the management of chronic psoriasis: new approaches and emerging treatment options. |
| Q37081486 | Update on the natural history and systemic treatment of psoriasis |
| Q34553755 | Use of biologic agents in combination with other therapies for the treatment of psoriasis |
| Q37418279 | Use of biologic therapeutics in difficult-to-treat psoriasis |
| Q37523846 | Ustekinumab: a new option in psoriasis therapy |
| Q33590255 | What is the impact of the new clinical trial data? What are the lessons for patient management? |
| Q33357138 | What's new in dermatological therapy? |
| Q38083175 | Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. |
| Q84027466 | [Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis] |
| Q84847318 | [Efficiency of biologic agents in the treatment of moderate to severe psoriasis] |
| Q46009980 | [Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología ]. |
| Q88141686 | [Side effects of biologic therapies in psoriasis] |
Search more.